Wegener's Granulomatosis: A Case Report*

Tyner, George S.

doi:10.1016/0002-9394(60)91010-2

Cited by 20 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Stabilizing kidney function is a paramount therapeutic goal. 23,24 Glucocorticoids-A Double-Edged Sword for AAV Induction Therapy A 1958 retrospective description of 56 patients with WG (now GPA) documented an average survival of 5 months, with kidney and respiratory failure the leading causes of death. 25 A literature review in 1967 described improved survival in 26 patients with GPA who received glucocorticoids (GCs) compared with no treatment (12.5 versus 5 months).…”

Section: Kidneys In Aavmentioning

confidence: 99%

Evolution of Therapy for ANCA-Associated Vasculitis with Kidney Involvement

Rajasekaran,

Rizk

2023

Kidney360

View full text Add to dashboard Cite

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) belongs to a group of small-vessel systemic vasculitides characterized by granulomatous and neutrophilic inflammation of various tissues. Patients often have circulating autoantibodies targeting neutrophilic antigens. Although AAV was once associated with severe end-organ damage and extremely high mortality rates, the use of glucocorticoids and cyclophosphamide led to a paradigm change in its treatment. Over the last 20 years, significant progress in understanding the immunopathogenesis of AVV has enabled development of targeted immunotherapies, providing a much better prognosis for patients. This review describes the evolution of treatment of AAV, particularly for patients with kidney involvement.

show abstract